{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:16:51Z","timestamp":1790705811283,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Wenzhou Basic Medical and Health Technology Project","award":["Y20210325"],"award-info":[{"award-number":["Y20210325"]}]},{"name":"Wenzhou Basic Medical and Health Technology Project","award":["Y20210024"],"award-info":[{"award-number":["Y20210024"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-023-02092-9","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T03:02:15Z","timestamp":1688007735000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["FAK inhibitor PF-562271 inhibits the migration and proliferation of high-grade serous ovarian cancer cells through FAK and FAK mediated cell cycle arrest"],"prefix":"10.1007","volume":"40","author":[{"given":"Qionghui","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianshu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyun","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6822-026X","authenticated-orcid":false,"given":"Feng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,29]]},"reference":[{"key":"2092_CR1","first-page":"561","volume":"91","author":"SM Penny","year":"2020","unstructured":"Penny SM. Ovarian cancer: an overview. Radiol Technol. 2020;91:561\u201375.","journal-title":"Radiol Technol"},{"key":"2092_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000479006","volume":"85","author":"M Kossai","year":"2018","unstructured":"Kossai M, Leary A, Scoazec JY, et al. Ovarian cancer: a heterogeneous disease. Pathobiology. 2018;85:41\u20139.","journal-title":"Pathobiology"},{"key":"2092_CR3","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1097\/AOG.0000000000002580","volume":"131","author":"U Menon","year":"2018","unstructured":"Menon U, Karpinskyj C, Gentry-Maharaj A. Ovarian cancer prevention and screening. Obstet Gynecol. 2018;131:909\u201327.","journal-title":"Obstet Gynecol"},{"issue":"4","key":"2092_CR4","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3390\/ijms20040952","volume":"20","author":"MA Lisio","year":"2019","unstructured":"Lisio MA, Fu L, Goyeneche A, et al. High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints. Int J Mol Sci. 2019;20(4):952.","journal-title":"Int J Mol Sci"},{"key":"2092_CR5","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/nrc4019","volume":"15","author":"DD Bowtell","year":"2015","unstructured":"Bowtell DD, Bohm S, Ahmed AA, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015;15:668\u201379.","journal-title":"Nat Rev Cancer"},{"key":"2092_CR6","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41568-022-00503-z","volume":"22","author":"LE Kandalaft","year":"2022","unstructured":"Kandalaft LE, Dangaj Laniti D, Coukos G. Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation. Nat Rev Cancer. 2022;22:640\u201356.","journal-title":"Nat Rev Cancer"},{"key":"2092_CR7","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.hoc.2018.07.010","volume":"32","author":"B Orr","year":"2018","unstructured":"Orr B, Edwards RP. Diagnosis and treatment of ovarian cancer. Hematol Oncol Clin North Am. 2018;32:943\u201364.","journal-title":"Hematol Oncol Clin North Am"},{"key":"2092_CR8","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11912-020-00933-8","volume":"22","author":"RD Mahmood","year":"2020","unstructured":"Mahmood RD, Morgan RD, Edmondson RJ, et al. First-line management of advanced high-grade serous ovarian cancer. Curr Oncol Rep. 2020;22:64.","journal-title":"Curr Oncol Rep"},{"key":"2092_CR9","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13045-020-00971-6","volume":"13","author":"M Govindarajan","year":"2020","unstructured":"Govindarajan M, Wohlmuth C, Waas M, et al. High-throughput approaches for precision medicine in high-grade serous ovarian cancer. J Hematol Oncol. 2020;13:134.","journal-title":"J Hematol Oncol"},{"key":"2092_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10585-019-09966-1","volume":"36","author":"JA Eble","year":"2019","unstructured":"Eble JA, Niland S. The extracellular matrix in tumor progression and metastasis. Clin Exp Metastasis. 2019;36:171\u201398.","journal-title":"Clin Exp Metastasis"},{"key":"2092_CR11","doi-asserted-by":"publisher","DOI":"10.1088\/1478-3975\/ac4390","author":"AD Doyle","year":"2022","unstructured":"Doyle AD, Nazari SS, Yamada KM. Cell-extracellular matrix dynamics. Phys Biol. 2022. https:\/\/doi.org\/10.1088\/1478-3975\/ac4390.","journal-title":"Phys Biol"},{"key":"2092_CR12","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1210\/en.2019-00206","volume":"160","author":"SE Townsend","year":"2019","unstructured":"Townsend SE, Gannon M. Extracellular matrix-associated factors play critical roles in regulating pancreatic beta-cell proliferation and survival. Endocrinology. 2019;160:1885\u201394.","journal-title":"Endocrinology"},{"key":"2092_CR13","doi-asserted-by":"crossref","unstructured":"Dolega ME, Monnier S, Brunel B, et al. Extracellular matrix in multicellular aggregates acts as a pressure sensor controlling cell proliferation and motility. Elife 2021; 10.","DOI":"10.7554\/eLife.63258"},{"key":"2092_CR14","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s13046-019-1265-1","volume":"38","author":"J Zhou","year":"2019","unstructured":"Zhou J, Yi Q, Tang L. The roles of nuclear focal adhesion kinase (FAK) on Cancer: a focused review. J Exp Clin Cancer Res. 2019;38:250.","journal-title":"J Exp Clin Cancer Res"},{"key":"2092_CR15","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.3390\/ijms23031726","volume":"23","author":"HH Chuang","year":"2022","unstructured":"Chuang HH, Zhen YY, Tsai YC, et al. FAK in Cancer: from mechanisms to therapeutic strategies. Int J Mol Sci. 2022;23:1726.","journal-title":"Int J Mol Sci"},{"key":"2092_CR16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3390\/biom10020179","volume":"10","author":"P Tapial Martinez","year":"2020","unstructured":"Tapial Martinez P, Lopez Navajas P, Lietha D. FAK structure and regulation by membrane interactions and force in focal adhesions. Biomolecules. 2020;10:179.","journal-title":"Biomolecules"},{"key":"2092_CR17","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41568-021-00340-6","volume":"21","author":"JC Dawson","year":"2021","unstructured":"Dawson JC, Serrels A, Stupack DG, et al. Targeting FAK in anticancer combination therapies. Nat Rev Cancer. 2021;21:313\u201324.","journal-title":"Nat Rev Cancer"},{"key":"2092_CR18","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.3390\/molecules26144250","volume":"26","author":"XJ Pang","year":"2021","unstructured":"Pang XJ, Liu XJ, Liu Y, et al. Drug discovery targeting focal adhesion kinase (FAK) as a promising cancer therapy. Molecules. 2021;26:4250.","journal-title":"Molecules"},{"key":"2092_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/13543776.2018.1414183","volume":"28","author":"PC Lv","year":"2018","unstructured":"Lv PC, Jiang AQ, Zhang WM, et al. FAK inhibitors in Cancer, a patent review. Expert Opin Ther Pat. 2018;28:139\u201345.","journal-title":"Expert Opin Ther Pat"},{"key":"2092_CR20","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.4155\/fmc-2021-0015","volume":"13","author":"M Mustafa","year":"2021","unstructured":"Mustafa M, Abd El-Hafeez AA, Abdelhafeez DA, et al. FAK inhibitors as promising anticancer targets: present and future directions. Future Med Chem. 2021;13:1559\u201390.","journal-title":"Future Med Chem"},{"key":"2092_CR21","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/13543784.2020.1740680","volume":"29","author":"A Mohanty","year":"2020","unstructured":"Mohanty A, Pharaon RR, Nam A, et al. FAK-targeted and combination therapies for the treatment of cancer: an overview of phase I and II clinical trials. Expert Opin Investig Drugs. 2020;29:399\u2013409.","journal-title":"Expert Opin Investig Drugs"},{"key":"2092_CR22","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1111\/cas.13256","volume":"108","author":"C Hu","year":"2017","unstructured":"Hu C, Chen X, Wen J, et al. Antitumor effect of focal adhesion kinase inhibitor PF562271 against human osteosarcoma in vitro and in vivo. Cancer Sci. 2017;108:1347\u201356.","journal-title":"Cancer Sci"},{"key":"2092_CR23","doi-asserted-by":"publisher","first-page":"108","DOI":"10.5937\/jomb0-32903","volume":"41","author":"Y Du","year":"2022","unstructured":"Du Y, Li S, Zhou T, et al. SIPA1 boosts migration and proliferation, and blocks apoptosis of glioma by activating the phosphorylation of the FAK signaling pathway. J Med Biochem. 2022;41:108\u201314.","journal-title":"J Med Biochem"},{"key":"2092_CR24","doi-asserted-by":"publisher","first-page":"5885387","DOI":"10.1155\/2023\/5885387","volume":"2023","author":"W Chen","year":"2023","unstructured":"Chen W, Wang J. RAB11A promotes cell malignant progression and tumor formation of prostate cancer via activating FAK\/AKT signaling pathway. Evid Based Complem Alternat Med. 2023;2023:5885387.","journal-title":"Evid Based Complem Alternat Med"},{"key":"2092_CR25","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1200\/JCO.2011.38.9346","volume":"30","author":"JR Infante","year":"2012","unstructured":"Infante JR, Camidge DR, Mileshkin LR, et al. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. J Clin Oncol. 2012;30:1527\u201333.","journal-title":"J Clin Oncol"},{"key":"2092_CR26","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/jcmm.17094","volume":"26","author":"JY Chen","year":"2022","unstructured":"Chen JY, Chen YJ, Liu L, et al. C1632 suppresses the migration and proliferation of non-small-cell lung cancer cells involving LIN28 and FGFR1 pathway. J Cell Mol Med. 2022;26:422\u201335.","journal-title":"J Cell Mol Med"},{"key":"2092_CR27","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s12094-017-1774-3","volume":"20","author":"C Yang","year":"2018","unstructured":"Yang C, Zhang J, Ding M, et al. Ki67 targeted strategies for cancer therapy. Clin Transl Oncol. 2018;20:570\u20135.","journal-title":"Clin Transl Oncol"},{"key":"2092_CR28","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.3892\/mmr.2014.2914","volume":"11","author":"LT Li","year":"2015","unstructured":"Li LT, Jiang G, Chen Q, et al. Ki67 is a promising molecular target in the diagnosis of cancer (review). Mol Med Rep. 2015;11:1566\u201372.","journal-title":"Mol Med Rep"},{"key":"2092_CR29","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ygyno.2021.04.015","volume":"162","author":"VG Gupta","year":"2021","unstructured":"Gupta VG, Hirst J, Petersen S, et al. Entinostat, a selective HDAC1\/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer. Gynecol Oncol. 2021;162:163\u201372.","journal-title":"Gynecol Oncol"},{"key":"2092_CR30","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s13402-021-00658-1","volume":"45","author":"X Yang","year":"2022","unstructured":"Yang X, Wu G, Zhang Q, et al. ACSM3 suppresses the pathogenesis of high-grade serous ovarian carcinoma via promoting AMPK activity. Cell Oncol (Dordr). 2022;45:151\u201361.","journal-title":"Cell Oncol (Dordr)"},{"key":"2092_CR31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13048-021-00877-y","volume":"14","author":"W Hu","year":"2021","unstructured":"Hu W, Li M, Chen Y, et al. UBE2S promotes the progression and Olaparib resistance of ovarian cancer through Wnt\/beta-catenin signaling pathway. J Ovarian Res. 2021;14:121.","journal-title":"J Ovarian Res"},{"key":"2092_CR32","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.addr.2010.11.001","volume":"63","author":"X Zhao","year":"2011","unstructured":"Zhao X, Guan JL. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Adv Drug Deliv Rev. 2011;63:610\u20135.","journal-title":"Adv Drug Deliv Rev"},{"key":"2092_CR33","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s000180050273","volume":"55","author":"DA Freedman","year":"1999","unstructured":"Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci. 1999;55:96\u2013107.","journal-title":"Cell Mol Life Sci"},{"key":"2092_CR34","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/j.bcp.2007.01.022","volume":"73","author":"N Nomura","year":"2007","unstructured":"Nomura N, Nomura M, Newcomb EW, et al. Geldanamycin induces G2 arrest in U87MG glioblastoma cells through downregulation of Cdc2 and cyclin B1. Biochem Pharmacol. 2007;73:1528\u201336.","journal-title":"Biochem Pharmacol"},{"key":"2092_CR35","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41580-021-00404-3","volume":"23","author":"HK Matthews","year":"2022","unstructured":"Matthews HK, Bertoli C, de Bruin RAM. Cell cycle control in cancer. Nat Rev Mol Cell Biol. 2022;23:74\u201388.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2092_CR36","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3390\/genes10110859","volume":"10","author":"JH Lee","year":"2019","unstructured":"Lee JH, Berger JM. Cell Cycle-Dependent Control and Roles of DNA Topoisomerase II. Genes (Basel). 2019;10:859.","journal-title":"Genes (Basel)"},{"key":"2092_CR37","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/nrm1549","volume":"6","author":"SK Mitra","year":"2005","unstructured":"Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol. 2005;6:56\u201368.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2092_CR38","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/nrc3792","volume":"14","author":"FJ Sulzmaier","year":"2014","unstructured":"Sulzmaier FJ, Jean C, Schlaepfer DD. FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer. 2014;14:598\u2013610.","journal-title":"Nat Rev Cancer"},{"key":"2092_CR39","first-page":"750","volume":"3","author":"DA Ucar","year":"2011","unstructured":"Ucar DA, Dang LH, Hochwald SN. Focal adhesion kinase signaling and function in pancreatic cancer. Front Biosci (Elite Ed). 2011;3:750\u20136.","journal-title":"Front Biosci (Elite Ed)"},{"key":"2092_CR40","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1007\/s10637-015-0282-y","volume":"33","author":"SF Jones","year":"2015","unstructured":"Jones SF, Siu LL, Bendell JC, et al. A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2015;33:1100\u20137.","journal-title":"Invest New Drugs"},{"key":"2092_CR41","doi-asserted-by":"publisher","first-page":"e47327","DOI":"10.7554\/eLife.47327","volume":"8","author":"CJ Diaz Osterman","year":"2019","unstructured":"Diaz Osterman CJ, Ozmadenci D, Kleinschmidt EG, et al. FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy. Elife. 2019;8:e47327.","journal-title":"Elife"},{"issue":"Pt 17","key":"2092_CR42","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1242\/jcs.113.17.3063","volume":"113","author":"J Zhao","year":"2000","unstructured":"Zhao J, Zheng C, Guan J. Pyk2 and FAK differentially regulate progression of the cell cycle. J Cell Sci. 2000;113(Pt 17):3063\u201372.","journal-title":"J Cell Sci"},{"key":"2092_CR43","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/bies.950170603","volume":"17","author":"EA Nigg","year":"1995","unstructured":"Nigg EA. Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle. BioEssays. 1995;17:471\u201380.","journal-title":"BioEssays"},{"key":"2092_CR44","first-page":"737","volume":"17","author":"TX Xie","year":"2000","unstructured":"Xie TX, Misumi J, Aoki K, et al. Absence of p53-mediated G1 arrest with induction of MDM2 in sterigmatocystin-treated cells. Int J Oncol. 2000;17:737\u201342.","journal-title":"Int J Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02092-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-023-02092-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02092-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:29:25Z","timestamp":1690331365000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-023-02092-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,29]]},"references-count":44,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["2092"],"URL":"https:\/\/doi.org\/10.1007\/s12032-023-02092-9","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,29]]},"assertion":[{"value":"18 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author(s) declare(s) that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"HGSOC tissues were collected with the approval of the Institutional Research Human Ethical Committee of the Wenzhou Medical University for the use of clinical biopsy specimens and informed written consent was obtained from patients. The ethics committee approval number of this study is No.YS2021-065.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"215"}}